Created On: 2020-07-15
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 275366
The product, Ofatumumab, is being commercialized by Licensee.
Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).
IPSCIO Record ID: 46309
IPSCIO Record ID: 271809
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell which normally produces antibodies.
IPSCIO Record ID: 26608
Acadesine is a nucleoside analogue with a novel mechanism of action, which unlike most existing treatments for B-CLL, has been shown, in an ex vivo study, to target B-cells selectively, while minimising toxicity to T-cells. The company believes that it may have reduced development risk, since it was well tolerated when previously studied for an unrelated indication. A proof-of-concept Phase I study in B-CLL, which is planned to be conducted in 2007, will investigate B-cell selectivity in patients with cancer.
IPSCIO Record ID: 190857